Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

NCT ID: NCT06217783

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-27

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives:

\- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.

Secondary Objectives:

1. Time from catheter placement to removal (i.e. survival or dwell time).
2. Per catheter length rate of failure analysis
3. Rate of repeat catheterization
4. Rate of infection
5. Rate of thrombosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oncologic Complications and Emergencies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Participants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you.

Group Type EXPERIMENTAL

Introcan Safety IV Catheter

Intervention Type DEVICE

Given by IV

Group B

Participants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you.

Group Type EXPERIMENTAL

Introcan Safety IV Catheter

Intervention Type DEVICE

Given by IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Introcan Safety IV Catheter

Given by IV

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 18 years old.
2. Provision of signed and dated informed consent form.
3. Predetermined to have difficult IV access necessitating USIV placement
4. Expected admission to hospital with anticipated stay \> 48 hours (per discussion with treating physician).

Exclusion Criteria

1. Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
2. Inability to give informed consent.
3. Pregnant women.
4. Non-English speaking participants.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jonathan Rowland, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MD Anderson Cancer Center

Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan Rowland, MD

Role: CONTACT

Phone: (832) 450-8954

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jonathan Rowland, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

MD Anderson Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2024-00503

Identifier Type: OTHER

Identifier Source: secondary_id

2023-0848

Identifier Type: -

Identifier Source: org_study_id